DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Gawrieh S, Noureddin M, Loo N. et al.
Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial.
Hepatology 2021;
74 (04) 1809-1824
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.